REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/21/2025
Back to search
Official data from USPTO
HINGE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HINGE THERAPEUTICS
ST13
US500000087983197Class
42
Filing
87983197
Registration
6108444
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
64
Latest update
07/22/2025
Trademark type
Word
Nice classes
42
Filing date
04/10/2017
Registration date
07/21/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/21/2020
Last transaction
07/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/01/2017
First use in commerce
03/01/2017
Drawing code
4
Owner type
03
Owner location
Sunnyvale, CA
Examiner
JOHNSON, AISHA
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Hinge Therapeutics, Inc.
Representatives
Neil A. Salyards Procopio, Cory, Hargreaves & Savitch LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
drug discovery services; pharmaceutical research and developmentproduct research and development; research and development services for discovery and development of protein therapeuticsprophylacticsdiagnosticstheranostics for the treatmentpreventionpalliationdiagnosis of diseases; research of pharmaceutical products for the diagnosis of human disease or human health-related conditions; research of pharmaceutical products for the prevention or treatment of human diseases or human health-related conditions; development and design of pharmaceutical products for the diagnosispreventiontreatment of human diseases or human health-related conditions
Publications
History of USPTO decisions and trademark events.
64 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/09/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/09/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/09/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/16/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/16/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/16/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/16/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/16/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/21/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/17/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/16/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/10/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/09/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
06/09/2020
EX5G
SOU EXTENSION 5 GRANTED
06/09/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/08/2020
IUAF
USE AMENDMENT FILED
05/27/2020
DRRR
DIVISIONAL REQUEST RECEIVED
05/27/2020
EXT5
SOU EXTENSION 5 FILED
05/27/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/27/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/27/2020
EISU
TEAS STATEMENT OF USE RECEIVED
05/27/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/05/2020
EX4G
SOU EXTENSION 4 GRANTED
02/03/2020
EXT4
SOU EXTENSION 4 FILED
02/03/2020
EEXT
SOU TEAS EXTENSION RECEIVED
02/03/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/18/2019
EX3G
SOU EXTENSION 3 GRANTED
07/16/2019
EXT3
SOU EXTENSION 3 FILED
07/16/2019
EEXT
SOU TEAS EXTENSION RECEIVED
07/16/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/08/2019
EX2G
SOU EXTENSION 2 GRANTED
02/06/2019
EXT2
SOU EXTENSION 2 FILED
02/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
02/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/07/2018
EX1G
SOU EXTENSION 1 GRANTED
08/04/2018
EXT1
SOU EXTENSION 1 FILED
08/04/2018
EEXT
SOU TEAS EXTENSION RECEIVED
08/04/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/12/2017
PUBO
PUBLISHED FOR OPPOSITION
12/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/22/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/04/2017
ALIE
ASSIGNED TO LIE
11/03/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/23/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/29/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/28/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/28/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2017
GNRT
NON-FINAL ACTION E-MAILED
09/14/2017
CNRT
NON-FINAL ACTION WRITTEN
09/14/2017
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
08/28/2017
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/08/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/30/2017
GNRT
NON-FINAL ACTION E-MAILED
06/30/2017
CNRT
NON-FINAL ACTION WRITTEN
06/30/2017
DOCK
ASSIGNED TO EXAMINER
06/30/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/17/2017
NWAP
NEW APPLICATION ENTERED
04/13/2017
Continuous trademark protection
Get notified about every new filing that threatens HINGE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.